Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3714170 | 0.87 | — | — | |
| SCHEMBL343240 | 0.84 | NR1H2 (0.33) | NR1H2USP2SMN1; SMN2RORCPIK3CD | |
| SCHEMBL23580609 | 0.79 | USP2 (0.35) | NR1H2USP2SMN1; SMN2RORCRECQL | |
| SCHEMBL29882268 | 0.77 | RORC (0.39) | NR1H2USP2SMN1; SMN2RORCRECQL | |
| SCHEMBL23580121 | 0.76 | NR1H2 (0.40) | NR1H2USP2SMN1; SMN2RORCPIK3CD | |
| SCHEMBL3654641 | 0.76 | NR1H2 (0.37) | NR1H2USP2SMN1; SMN2RORCMEN1 | |
| SCHEMBL23580088 | 0.76 | PDE4A (0.36) | NR1H2USP2SMN1; SMN2RORCPIK3CD | |
| SCHEMBL23608680 | 0.73 | USP2 (0.35) | NR1H2USP2SMN1; SMN2RORC | |
| SCHEMBL342911 | 0.73 | NR1H2 (0.37) | NR1H2USP2SMN1; SMN2RORCPIK3CD | |
| SCHEMBL31663113 | 0.72 | USP2 (0.37) | NR1H2USP2SMN1; SMN2RECQLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263632-B2 | Aminopyridine derivatives having Aurora A selective inhibitory action | VERTEX PHARMACEUTICALS INCOPORATED (US) | 2012-09-11 | — | — | US | disclosed |
| EP-2411012-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | MSD K.K. (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20120015940-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20120015940-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015940-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | AURKA, AURKC, AURKB | NR1H2 2813/4885USP2 4061/4885SMN1; SMN2 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.